Brainstorm Cell Therapeutics Inc. (BCLI)
-OTC BB 0.21 Jun 18, 3:34PM EDT|Pre-Market
:
NaN
| Prev Close: | 0.21 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 0.76 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 0.17 - 0.38 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 160,567 |
|---|
| Market Cap: | 31.31M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.03 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- BrainStorm Treats 8th Patient in Phase IIa Trial; Completes Enrollment of Final 4 PatientsMarketwired(Mon, Jun 10)
- BrainStorm Submits Favorable Interim Safety Report for First Group of Patients in Its Phase IIa Dose-Escalating TrialMarketwired(Wed, Jun 5)
- BrainStorm Receives 1.2 Million NIS Grant From Israel's Office of the Chief ScientistMarketwired(Tue, Jun 4)
- BrainStorm Announces CEO Interview With The Wall Street AnalystMarketwired(Thu, May 23)
- BrainStorm Provides Update on Clinical Trial and Scientific Conference ActivitiesMarketwired(Tue, May 21)
- BRAINSTORM CELL THERAPEUTICS INC. FinancialsEDGAR Online Financials(Fri, May 17)
- BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, May 9)
- LifeSci Advisors Initiates Coverage of Brainstorm Cell TherapeuticsMarketwired(Tue, Apr 30)
- BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Tue, Apr 23)
- Investing In The Stem Cell Sector: An Overviewat Seeking Alpha(Wed, Apr 17)
- BrainStorm to Present at Several Scientific and Investment ConferencesMarketwired(Wed, Apr 10)
- BrainStorm Partners With Dana-Farber for NurOwn(TM) Production in Phase II ALS Clinical TrialMarketwired(Mon, Apr 8)
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapyat Seeking Alpha(Thu, Mar 28)
- 2 Biopharma Stocks Rallying On Fresh Clinical Trial Dataat Seeking Alpha(Thu, Mar 21)
- Results of NurOwn(TM) Clinical Trial Suggest Efficacy in ALS PatientsMarketwired(Thu, Mar 21)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis.
View More 
0.91%